Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hidaka-shi
Clinical trial register · Japan

Clinical Trials in Hidaka-shi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca32 Daiichi Sankyo4 Incyte Corporation4 Ono Pharmaceutical Co., Ltd.2 Jazz Pharmaceuticals1
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Hidaka-shi

43 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe
2026-09-24
Recruiting
AstraZeneca
Phase 3
950
Fukushima, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kawasaki-shi, Kobe, Kōtoku
2026-09-16
Recruiting
Incyte Corporation
Phase 3
700
Akashi-shi, Chiba, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kawasaki-shi, Kita-gun
2026-03-05
Recruiting
AstraZeneca
Phase 3
1,100
Akashi-shi, Chūōku, Hidaka-shi, Kashiwa, Kobe, Kōtoku, Kurume-shi, Nagoya
2025-12-29
Recruiting
Incyte Corporation
Phase 3
466
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Minatoku, Nagoya, Okayama
2025-12-09
Recruiting
Incyte Corporation
Phase 2
160
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Sapporo, Sunto-gun
2025-11-12
Recruiting
Daiichi Sankyo
Phase 3
686
Hidaka-shi, Hirakata-shi, Hirosaki-shi, Kashiwa-shi, Kawasaki-shi, Kitakyushu-shi, Kumamoto, Kurume-shi
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
710
Akashi-shi, Fukuoka, Fukushima, Hidaka-shi, Kōtoku, Kurume-shi, Niigata, Okayama
2025-09-30
Recruiting
AstraZeneca
Phase 3
800
Chūōku, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kōtoku, Kurume-shi, Matsuyama, Minatoku
2025-08-01
Recruiting
AstraZeneca
Phase 2
100
Chūōku, Fukuoka, Hidaka-shi, Kashiwa, Kitaadachi-gun, Kōtoku, Nagoya, Osaka
2025-07-17
Recruiting
AstraZeneca
Phase 3
600
Akashi-shi, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa, Kashiwa-shi, Kobe, Kōtoku
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
582
Akashi, Chūōku, Fukushima, Hidaka-Shi, Kōtoku, Kurume-shi, Nagoya, Niigata
2025-03-19
Recruiting
AstraZeneca
Phase 3
840
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hidaka-shi, Hirakata-shi, Hiroshima, Kasama-shi
2025-03-01
Active, closed
AstraZeneca
Phase 3
25
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Iwakuni-shi, Kashiwa
2024-10-15
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Isesaki-shi, Kagoshima, Kyoto
2024-08-13
Recruiting
AstraZeneca
Phase 3
788
Chiba, Hidaka-shi, Hirakata-shi, Isehara-shi, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2024-08-01
Recruiting
AstraZeneca
Phase 3
675
Bunkyō City, Fukuoka, Hakodate-shi, Hidaka-shi, Hirakata-shi, Hirosaki-shi, Hiroshima, Kanazawa
2024-04-11
Recruiting
Daiichi Sankyo
Phase 2/3
860
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Kashiwa-shi, Kōtoku, Minatoku, Nagaizumi-cho
2024-02-27
Recruiting
AstraZeneca
Phase 3
1,145
Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe
2023-12-14
Recruiting
AstraZeneca
Phase 3
625
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu, Hidaka-shi
2023-11-23
Recruiting
AstraZeneca
Phase 3
800
Fukuoka, Ginowan-shi, Hidaka-shi, Kagoshima, Kōtoku, Kurume-shi, Maebashi, Matsuyama
2023-09-22
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Hidaka-shi, Kashiwa, Kōtoku, Sunto-gun, Tokyo
2023-06-05
Recruiting
AstraZeneca
Phase 3
4,300
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Hirakata-shi, Hiroshima, Isehara-shi
2023-03-31
Active, closed
AstraZeneca
Phase 3
1,350
Bunkyō City, Chūōku, Hamamatsu, Hidaka-shi, Hirosaki-shi, Hiroshima, Kumamoto, Nagoya
2022-12-29
Active, closed
Incyte Corporation
Phase 1
291
Aichi, Chiba-ken, Hidaka-shi, Tokyo
2022-07-05
Active, closed
AstraZeneca
Phase 3
791
Bunkyō City, Chiba, Fukuoka, Hidaka-shi, Hirosaki-shi, Itabashi-ku, Kashihara-shi, Kōtoku
2022-02-18
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 3
626
Kashiwa-shi, Yokohama, Osaki-shi, Suita-shi, Hidaka-shi, Ina-machi, Kitaadati-gun, Nagaizumi-Cho, Sunto-Gun, Bunkyo-ku
2021-11-05
Active, closed
AstraZeneca
Phase 3
927
Chūōku, Hidaka-shi, Hiroshima, Kawasaki-shi, Kōtoku, Nagoya, Ota-shi, Shinjuku-ku
2021-10-25
Recruiting
AstraZeneca
Phase 1/2
460
Chūōku, Hidaka-shi, Kashiwa, Kōtoku, Kurume-shi, Sunto-gun
2021-10-18
Active, closed
AstraZeneca
Phase 3
315
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Kitaadachi-gun, Kōtoku, Kumamoto, Matsuyama
2021-06-30
Active, closed
AstraZeneca
Phase 3
893
Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto
2021-05-10
Active, closed
AstraZeneca
Phase 3
1,157
Akashi-shi, Aomori, Bunkyō City, Chiba, Chūōku, Fukushima, Hidaka-shi, Hiroshima
2021-04-26
Active, closed
AstraZeneca
Phase 3
1,371
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Isehara-shi, Kitaadachi-gun, Kōtoku, Kumamoto
2021-01-28
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
40
Kashiwa-shi, Kobe, Yokohama, Ina, Osaka, Takatsuki-shi, Hidaka-shi, Koto-Ku
2021-01-13
Active, closed
AstraZeneca
Phase 3
957
Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kochi, Kurume-shi
2020-11-17
Active, closed
AstraZeneca
Phase 3
640
Bunkyō City, Chūōku, Hidaka-shi, Hirakata-shi, Hiroshima, Kashiwa, Kitaadachi-gun, Kōtoku
2020-10-19
Active, closed
AstraZeneca
Phase 3
866
Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Gifu, Hidaka-shi, Hiroshima
2020-07-24
Active, closed
AstraZeneca
Phase 3
818
Chiba, Fukuoka, Fukushima, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku
2020-04-16
Active, closed
AstraZeneca
Phase 3
587
Bunkyō City, Fukuoka, Hidaka-shi, Himeji-shi, Iwakuni-shi, Kanazawa, Kashiwa, Kōtoku
2019-07-02
Active, closed
AstraZeneca
Phase 3
923
Bunkyō City, Fukuoka, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku, Kumamoto
2019-06-25
Active, closed
AstraZeneca
Phase 3
1,837
Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kashiwa
2014-04-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Matsuyama, Niigata, Osakasayama-shi, Sapporo
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Matsuyama, Niigata, Sapporo, Sunto-gun
2013-08-26
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/hidaka-shi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies with a site in Hidaka-shi.

How many clinical trials are recruiting in Hidaka-shi?

23 of the 43 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hidaka-shi), 43 studies
PhaseStudiesRecruitingShare
Phase 3361883.7%
Phase 1204.7%
Phase 1/2224.7%
Phase 2224.7%
Phase 2/3112.3%

Most active sponsors

Lead sponsors with the most studies (Hidaka-shi)
Lead sponsorStudiesRecruiting
AstraZeneca3215
Daiichi Sankyo44
Incyte Corporation43
Ono Pharmaceutical Co., Ltd.20
Jazz Pharmaceuticals11
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.